CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy 2022 | December, 2022